Original ArticleBortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)
Cited by (0)
Disclosure: The authors declare no conflicts of interest.
This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants: CA-25224, CA-37404, CA-15083, CA-63848, CA-35195, CA-35090, CA-35269, CA-37417, CA-52654, CA-35267, CA-63849, CA-35113, CA-60276, CA-35119, CA-35103, and CA-35431.
Additional participating institutions include: Siouxland Hematology-Oncology Associates, Sioux City, IA 51105 (Donald B. Wender, MD); Missouri Valley Cancer Consortium, Omaha, NE 68131 (Gamini S. Soori, MD); Mayo Clinic Jacksonville, Jacksonville, FL 32224 (Edith Perez, MD); Duluth CCOP, Duluth, MN 55805 (Daniel A. Nikcevich, MD); Medcenter One Health Systems, Bismarck, ND 58506 (Edward J. Wos, D.O.); Meritcare Hospital CCOP, Fargo, ND 58122 (Preston D. Steen, MD); Upstate Carolina CCOP, Spartanburg, SC 29303 (James D. Bearden, III, MD); Abbott Northwestern Hospital, Minneapolis, MN 55407 (Daniel J. Schneider, MD); Mayo Clinic Scottsdale, Scottsdale, AZ 85259-5404 (Tom R. Fitch, MD); Mobile Infirmary Medical Center, Mobile, AL 36607 (Paul Schwarzenberger, MD).